1. Introduction {#s0005}
===============

The past two decades have seen a rapid uptake in interventions designed to address the persistent and treatment-resistant cognitive challenges that attend schizophrenia ([@bb0100]). Cognitive deficits are observed in clinically high-risk, first episode ([@bb0040]), and chronic phases of psychosis ([@bb0145]). Two commonly applied models of non-pharmacological intervention to address these challenges are compensatory and restorative approaches. A prominent compensatory intervention is cognitive adaptation training (CAT). CAT addresses the functional impacts of cognitive impairments through the use of home-based environmental supports such as signs, alarm reminders, checklists, and behavioral cueing to bypass cognitive and motivational challenges ([@bb0160]). CAT has demonstrated medium to large effects on community functioning and treatment adherence in schizophrenia populations ([@bb0195], [@bb0200], [@bb0205]). Improvements in neurocognition have been observed in CAT trials. However, neurocognition has not been found to be a significant mediator of the effects of CAT on community functioning ([@bb0095]).

The most studied restorative intervention to address cognitive deficits is cognitive remediation (CR). CR seeks to improve cognitive and community functioning through a range of repeated cognitive task practice and strategy acquisition activities ([@bb0225]). Despite the wide range of CR approaches, meta-analyses reveal consistent and durable effects in the medium range on cognitive functioning ([@bb0165], [@bb0170]; [@bb0225]). The effects of CR on community functioning are variable. It has been observed that unless CR is integrated into broader psychiatric rehabilitation interventions such as supported employment ([@bb0165], [@bb0170]) and education ([@bb0115]), or closely paired with strategy monitoring and real-world task simulation ([@bb0055]), functional impacts are less robust.

Investigation into CAT and CR targeting early illness phase populations are less developed literatures. A small feasibility study found good engagement and acceptance of CAT interventions in an early psychosis population ([@bb0005]). Among early intervention populations CR has been found feasible ([@bb0060]; [@bb0070]) and effective in cognitive and social domains ([@bb0090]; [@bb0175]). Some studies comparing outcomes as a function of age have also indicated greater effects of CR on cognitive functioning for younger participants ([@bb0050]; [@bb0130]), though this finding is not consistent across all such analyses ([@bb0165], [@bb0170]; [@bb0225]).

The present study was designed to contribute to the evidence base examining cognitive interventions in early psychosis treatment and explore the relative effects of primarily compensatory and restorative interventions. The study design was a randomized trial comparing the effects of CAT and Action Based Cognitive Remediation (ABCR) with community functioning as the primary outcome. Previous evidence was not available to inform hypotheses as to one intervention being more effective than the other, so the question of relative benefit was exploratory. Secondary outcomes included goal attainment, hospitalization, medication adherence, symptomatology and neurocognition.

2. Methods {#s0010}
==========

2.1. Study design {#s0015}
-----------------

Participants with psychosis were recruited through both inpatient and outpatient services at a tertiary psychiatric facility and other local outpatient community mental health services in a large urban center in Canada. They were block randomized into CAT and ABCR in stage one and, in a second stage in which a combined version of ABCR+CAT was piloted, were randomize into the combined intervention (data from the combined intervention is reported elsewhere due to the small sample size). The treatment period was 4 months with one follow up assessment at 5 months post-treatment. The assessor was blinded to treatment condition and treatment providers only provided a single type of treatment. Two assessors were used over the course of the trial who cross-trained to \>80% reliability on scale delivery. The study was initiated in 2015 with the last follow up data collected in March, 2018.

2.2. Participants {#s0020}
-----------------

Participants were identified through a centralized recruitment process in inpatient and outpatient early psychosis services at the primary site and through clinician referral from other local sites. All participants provided written consent with forms with processes approved by an Institutional Review Board and with procedures in line with internationally recognized ethical standards. The study was registered through [clinicaltrials.gov](http://clinicaltrials.gov){#ir0005} (\#[NCT02430935](NCT02430935){#ir0010}). Of the 69 participants who signed consent, 56 were randomized into CAT and ABCR arms of whom, in turn, follow up data was obtained for 39 (consort diagram -- [Fig. 1](#f0005){ref-type="fig"}). The Mini International Neuropsychiatric Interview was used to confirm diagnosis. Participants were between 17 and 34 years of age, were fluent English speakers, and most were prescribed oral or depot anti-psychotic medication (96%). Prospective participants were excluded if a clinician diagnosis of intellectual disability was identified. To control for variability in support level in the follow up period, all participants were required to have an outpatient case manager in addition to physician support. In the case of multiple diagnoses, Psychosis NOS, and Bipolar Disorder with Psychotic features (noting shifting diagnoses are common in early intervention), participants were included if structured interview, chart and clinician aligned in identifying psychosis as the primary clinical concern. Of the 56 participants from whom baseline data was obtained, the mean age was 27 years (*SD* = 4.5), 36 were male, 30 were White, 8 were of African Descent, 6 were East Asian, 5 South Asian, 2 Latin American and 5 indicated other ethnicity. With respect to education, attainment groupings included grades 7--12 without graduation (27%), high school graduation (32%), and some community college or university (41%) (see [Table 1](#t0005){ref-type="table"}).Fig. 1Consort diagram.Fig. 1Table 1Participant demographics at baseline.Table 1VariableABCRCATp-Value[⁎](#tf0005){ref-type="table-fn"}N%N%Categorical variables Gender0.47 Male14582269 Female1042928 Transsexual0013 Ethnicity0.40 Aboriginal0000 African Descent417413 Caucasian13541753 East Asian28413 Latin-American0026 South Asian14413 Other41713 Living situation0.40 lives alone in a private dwelling8331135 lives with spouse and children in private dwelling1400 lives with parents in private dwelling14581445 Rooming/boarding home00310 Supportive housing14310 Education0.38 Grade 6 or less0000 Grade 7 to 12 (without graduating high school)5211031 Graduated high school or high school equivalent938928 Part college/university521928 Graduated 2-year college41713 Graduated 4-year undergraduate1439 Part graduate/professional school0000 Completed graduate or professional school0000 Employment status0.21 Employed full time2826 Employed part time00516 Employed casually1426 Unemployed21882372 Time last hospitalized0.29 01400 \<1 week00310 1--4 weeks1413  \> 4 weeks21912687 Diagnosis1.00 Schizophrenia19832374 Schizoaffective417516 PD-NOS0013 Bipolar II - psychotic0013 Psychosis0013 Comorbidity0.69 Schizophrenia0019 Schizoaffective0000 Depression117436 Dyslexia0000 Bipolar disorder23319 Psychosis00218 OCD11719 PTSD23319 Anxiety0019  Continuous variablesMean (SE)Mean (SE)p-Value[⁎⁎](#tf0010){ref-type="table-fn"}Age26.1(0.9)27.8(0.8)0.22Age 1st hospitalized20.5(1.0)22.4(0.7)0.04Total number of hospitalizations in past year0.5(0.2)1.0(0.2)0.29Total number of days in hospital in past year1.6(0.7)22.6(10.5)0.04Total number of ER visits0.7(0.2)0.9(0.2)0.52Medication adherence93.9(2.5)94.1(3.6)0.15Wide range achievement test-III59.3(1.3)59.3(1.8)0.365[^1][^2]

2.3. Treatment groups {#s0025}
---------------------

All treatments were manualized and designed to be delivered weekly for up to 4 months/16 visits. Sessions lasted from 1 to 2 h with missed sessions rescheduled within the same week when possible.

### 2.3.1. CAT {#s0030}

CAT is a manualized, home-based intervention emphasizing environmental supports (checklists, signs, alarms) and compensatory strategies that are delivered on a weekly basis by the CAT specialist ([@bb0160]; [@bb0200], [@bb0205]). Building from initial behavioral, environmental, and cognitive assessments, individuals with poorer executive functioning require greater structure, more finely articulated steps, and more obvious cues and vice versa. Greater apathy requires more cueing and sequencing and more disinhibition requires the removal of distractions and better organization. Mixed profiles indicate combinations of the above approaches. Environmental supports are tailored to the individual\'s environment, needs, and recovery goals. Supports are established and maintained over the course of weekly home visits.

### 2.3.2. ABCR {#s0035}

ABCR is a manualized, group-based intervention ([@bb0055]) that is provided weekly for 16 weeks in 1--2 h sessions. Scientific Brain Training Pro is used for computerized cognitive drill and practice exercises. This is an online program delivered by tablet in group sessions with participants in the present study provided with tablets for the duration of the intervention for home-based practice to ensure technology access. A total of 15 gamified exercises were used for training in attention, processing speed, visual, verbal and working memory, and executive functioning domains. In-group practice was augmented by homework practice, with participants advised to complete 20 min per day. In groups, computer exercises were complemented by strategy monitoring. Transferring to real world tasks is the second element of ABCR and involves the practice of simulated work, social, and recreational tasks and role-plays.

2.4. Assessments {#s0040}
----------------

### 2.4.1. Primary outcomes {#s0045}

The primary measure of functional outcome was the Multnomah Community Ability Scale (MCAS; [@bb0020]). Here we report both MCAS scores derived from participant interview as well as clinician (primary case manager) rated MCAS scores (cMCAS). Global level of social and occupational functioning was obtained using the Social and Occupational Functioning Scale (SOFAS; [@bb0015]) and engagement in functional activities was assess with the Social Functioning Scale (SFS; [@bb0035]).

### 2.4.2. Secondary outcomes {#s0050}

To track progress on personal community recovery goals, Goal Attainment Scaling (GAS; [@bb0105]) was used. GAS identifies up to 5 operationalized goals anchored of a five point scale representing less attainment (−2, −1), achieved (0), and over-attained (+1, +2). Symptoms over the past week were assessed using the expanded version of the Brief Psychiatric Rating Scale (BPRS-E; [@bb0210]). The total score was used as a measure of global symptomatology and the psychosis symptom subscale was examined specifically. Negative symptoms were assessed using the Negative Symptom Assessment (NSA; [@bb0010]). The Wide Range Achievement Test (WRAT-III; [@bb0215]) reading subtest was used to evaluate pre-morbid intelligence. The Trail Making Test Part A ([@bb0185]) was used to assess scanning ability and psychomotor speed. Short term memory was evaluated with the digit span subtest of the Weschler Adult Intelligence Scale ([@bb0190]). Verbal learning and memory was assessed with the California Verbal Learning Test ([@bb0080]). Executive functioning was assessed with the Trail Making Test, Part B ([@bb0185]), and the Wisconsin Card Sorting Test (WCST; [@bb0030]). Sustained attention/vigilance was examined using Digit Vigilance Test (DVT; [@bb0110]). Global cognition was the focus of analyses with the metric calculated as the mean of neurocognition assessment z scores. Key demographics were collected along with hospitalization history with medication adherence as assessed with the Brief Adherence Rating Scale ([@bb0065]).

2.5. Data analysis {#s0055}
------------------

All subjects that were initially randomized and had baseline data were analyzed (Intention to Treat Analysis). Initial descriptive analyses were conducted comparing baseline demographics and primary clinical measures across groups. Fisher\'s Exact test was used for categorical variables and the non-parametric Kruskal-Wallis H test was used for continuous variables. Means (Standard Errors) are reported and a confidence level of 0.05 was adopted along with two tailed tests. The primary analysis was conducted through Linear Mixed Effect Models, where treatment (ABCR, CAT), time (Baseline, 4 Months, 9 Months) and the treatment by time interaction was considered the fixed effect and individual subjects as random effects. Time was considered a categorical predictor. Mixed Effect Models addressed missing values in the outcome (mostly caused by attrition) through Full Maximum Likelihood estimation, which uses all available information in the data and is unbiased under Missing At Random (MAR) assumption. When reported, effects in terms of difference of means are model adjusted effects. Number Needed to Treat (NNT) was reported for binary and continuous data ([@bb0140]). Cohen\'s d is reported for outcome analyses except when all three time points are analyzed in which case Cohen\'s f is reported ([@bb0075]). In a secondary analysis the 9 month follow up data was included and models were rerun. All analyses were conducted with R version 3.4.4., with Linear Mixed Effect Models adjusted with the R package and lme4 and p-values used with the Satterthwaite method for calculating the denominator degree of freedom using lmerTest ([@bb0025]; [@bb0150]; [@bb0180]).

3. Results {#s0060}
==========

There were no statistically significant treatment group differences on primary demographics nor baseline WRAT ([Table 1](#t0005){ref-type="table"}). Age of First Hospitalization was significantly older for the CAT treatment group (p = 0.04) and the number of days hospitalized in the past year was higher for the CAT group (p = 0.04). No primary outcomes presented significant differences at baseline. Of the secondary outcomes a difference was observed on baseline GAS ratings (p = 0.01) with the CAT group (1.88(0.08)) having higher GAS mean rankings than ABCR (1.88 vs. 1.47). None of these significant differences would survive a Bonferroni adjustment for all comparisons done at baseline and it was concluded that randomization was successful. Total participant numbers were: baseline n = 56; 4 months n = 39; 9 month follow up n = 31 ([Fig. 1](#f0005){ref-type="fig"}).

3.1. Primary outcomes {#s0065}
---------------------

Mixed effects analysis was used to test effects on functional outcomes measured by the MCAS, cMCAS, SOFAS and SFS. While medium-large effects of time were observed at outcome on the MCAS and cMCAS respectively ([Fig. 2](#f0010){ref-type="fig"}; MCAS (F(1,90) = 20.45, p \< 0.001, NNT = 2.6, d = 0.49); cMCAS F(1,65) = 21.59, p \< 0.001, NNT = 1.5, d = 0.75) with increases of 5.22(1.12) points in cMCAS and 4.52(1.00) points in MCAS mean scores, *there were no significant between treatment group differences*. Similarly, there was a time effect in the medium range for the SOFAS (F(1,89) = 9.18, p = 0.00, NNT = 2.6, d = 0.56) with an increase of 4.6(1.5) points, but no treatment group difference. No significant findings were observed for most SFS subscales. However, a treatment group difference approached significance in the medium effect range for the prosocial activities subscale (F(1,87) = 3.90, p = 0.05, NNT = 2.8, d = 0.44), suggesting a decrease in pro-social activity in the ABCR group compared an increase in the CAT group.Fig. 2Community functioning outcomes.Fig. 2

Incorporating 9-month follow-up data ([Table 2](#t0010){ref-type="table"}), a significant, moderate time by treatment effect was observed on the MCAS (F(2,118) = 4.55, p = 0.01, eta2 = 0.03, Cohen\'s f = 0.28). This effect reflected a sustained increase in MCAS adjusted mean score in the ABCR group (from baseline to 4 months: 6.14(1.56), t(118) = 3.93, p = 0.00) and from baseline to 9 months: 8.24(1.79), t(118) = 4.61, p \< 0.00) contrasted with a smaller increase from Baseline to 4 months in the CAT group (2.82(1.28), t(118) = 2.20, p = 0.033) with no significant change from 4 months to follow up. No such effect was evident for the cMCAS. At 9 months, a large time effect was observed on the SOFAS (F(2,90) = 9.36, p = 0.0002, eta2 = 0.06, Cohen\'s f = 0.44) without a significant treatment group difference. Considering SFS subscales at follow up, differences between treatment groups were not evident, though moderate time effects were observed for prosocial activities (F(2,82) = 5.35, p = 0.01, eta2 = 0.03, Cohen\'s f = 0.31), interpersonal behavior (F(2,87) = 4.19, p = 0.02, eta2 = 0.08, Cohen\'s f = 0.30), independence-performance (F(2,90) = 7.29, p = 0.00, eta2 = 0.05, Cohen\'s f = 0.36) and independence-competence (F(2,116) = 4.20, p = 0.02, eta2 = 0.03, Cohen\'s f = 0.27).Table 2Goal Attainment and Symptomology from Baseline, Post to Follow Up by Group.Table 2ABCRCATGroup × time mixed modelBaselinePostFollow-upBaselinePostFollow-upMean(SE)Mean(SE)Mean(SE)Mean(SE)Mean(SE)Mean(SE)dfF.valuePr(\>F)Functioning MCAS total66.5(1.32)71.87(2.00)74.6(1.93)67.69(1.39)70.29(1.20)70.75(1.08)2/1184.550.01 Clinician MCAS total62.25(1.67)68.77(2.26)69.6(2.52)61.83(1.57)67.5(2.10)67.36(2.79)2/600.920.40 Social functioning scale Employment/occupation4.04 (0.51)3.92 (0.75)5.00 (1.07)4.68 (0.53)5.13 (0.68)4.79 (0.84)2/890.150.86 Independence/competence33.13 (0.89)33.57 (1.73)36.40 (0.81)33.06 (0.98)35.61 (0.84)34.85 (1.23)2/1161.400.25 Independence/performance25.75 (2.06)26.36 (3.11)31.80 (3.22)28.28 (1.22)31.13 (1.19)32.30 (1.35)2/901.090.34 Interpersonal behaviour7.08 (0.29)7.71 (0.38)8.00 (0.45)6.90 (0.37)6.92 (0.42)7.47 (0.34)2/871.390.25 Prosocial activities24.29 (2.50)22.50 (3.11)19.30 (2.31)19.65 (1.58)20.25 (2.51)17.45 (1.89)2/821.730.18 Recreation19.29 (1.76)22.57 (2.63)20.50 (2.18)17.97 (1.09)18.21 (2.02)18.65 (1.38)2/880.320.73 Social engagement/withdrawal9.92 (0.48)10.14 (0.58)11.30 (0.67)10.10 (0.36)10.17 (0.39)10.35 (0.41)2/891.060.35 Social & occupational functioning scale52.75 (2.53)57.70 (4.33)63.30 (3.59)50.22 (2.39)56.63 (2.81)59.80 (2.43)2/900.790.46Goal attainment GAS1.47(0.10)3.55(0.27)3.55(0.73)1.88(0.08)3.57(0.10)3.48(0.29)2/720.870.42Symptomology BPRS total36.52(1.75)35.93(1.94)35.78(2.03)36.9(1.26)36.92(1.55)39.79(1.92)2/791.160.32 NSA global2.58(0.17)2.64(0.32)3(0.26)2.94(0.16)3(0.19)3.42(0.26)2/870.280.76

3.2. Secondary outcomes {#s0070}
-----------------------

The GAS evidenced a large time effect (F(1,44) = 241.50, p \< 0.00) with an increase in adjusted mean of 1.80(0.12) points from baseline to 4 months that remained significant at follow up (F(2,72) = 99.77, p \< 0.00, eta2 = 0.64, Cohen\'s f = 1.57). No difference between treatment groups was observed in goal attainment. No significant change was observed for Total BPRS nor for the psychoticism subscale of the BPRS at outcome and follow up. While outcome effects on negative symptoms were not observed on the NSA, a moderate time effect was evident at follow up (F(2,87) = 5.12, p = 0.01, eta2 = 0.05, Cohen\'s f = 0.32) again without a treatment group difference. There were no significant effects on days in hospital at outcome and follow up. However, a significant time effect in the moderate range was observed for ER visits at follow up (F(2, 106) = 4.32, p = 0.16, eta2 = 0.05, Cohen\'s f = 0.29) which reflected an overall decrease in ER visits for both treatment groups. No effects were observed for medication adherence, likely due to a ceiling effect. A composite score was created to represent overall neurocognition by averaging the z-score versions of each neurocognition scale (r = 0.75). No effects were observed at outcome nor follow up for this composite score. Changes were observed in some individual tests are reported in [Supplemental file 1](#ec0005){ref-type="supplementary-material"}.

4. Discussion {#s0075}
=============

With respect to the comparison of CAT to ABCR on change in functional outcome in an early psychosis population, we found medium-large effect size improvements in individuals randomized to either intervention. Considering follow up data, functioning in the CAT group stabilized as previously observed in an older psychosis population ([@bb0120]), while functioning in the ABCR group continued to improve in the 5-month post treatment period. Changes in symptomatology proved modest which is consistent with previous CAT and CR trials ([@bb0200]; [@bb0165], [@bb0170]). As observed previously for both CAT and ABCR ([@bb0095]; [@bb0055]), global cognition did not change significantly. Taken as a whole, these findings speak to the relevance of both CAT and ABCR for early psychosis populations, wherein they had to date not been substantively studied for effects and only preliminary evidence existed ([@bb0055]; [@bb0005]). The continued improvement in ABCR at follow up, or 'sleeper effect', is not unusual in restorative training programs and may speak to a degree of relative superiority of cognitive remediation in early psychosis populations. This hypothesis would require further testing to be confirmed, however, and attention would also need to be given to the influence of process variables of these quite different approaches (e.g., in home, outreach intervention with CAT and within clinic, group-based intervention with ABCR).

Implementation is also a key practice consideration for these cognitive interventions ([@bb0220]). Both are resource intensive, which affects both feasibility and viability in under-resourced mental health systems. Efforts to optimize access and cost-effectiveness will be essential to bringing compensatory and restorative cognitive interventions to scale. Examples include remotely-delivered CR ([@bb0085]), CAT implementation by family supports ([@bb0125]) and, more broadly, efforts to generate evidence to inform the targeting of treatment for subpopulations likely to receive the most benefit ([@bb0220]),

These findings are limited due to power concerns. The lack of treatment group effect difference at outcome and the treatment group difference at follow up need to be interpreted cautiously and will require replication with a larger sample in future work. Generalizability outside of the context of a large urban tertiary care facility in Canada is also a consideration. The lack of treatment as usual and placebo control conditions also limit the degree to which this analysis can provide a clear articulation of the relative effects of each intervention. Finally, it would benefit the field to continue this type of comparative method in different contexts and to use multi-site and pooled data approaches to parse out for whom benefit is optimized as a function of treatment type -- be its\' emphasis compensatory, restorative or a combination of both.

The following is the supplementary data related to this article.Supplemental File 1Changes in Cognitive Measures from Baseline, Post to Follow Up by Group.Supplemental File 1
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[^1]: Categorical variables compared using Fisher Test.

[^2]: Continuous variables compared using Mann-Whitney *U* Test.
